ChemoCentryx, Inc. is a biopharmaceutical company headquartered in Mountain View, California. Founded in 1997, it specialized in the discovery, development, and commercialization of orally administered small-molecule therapeutics targeting chemokine and chemoattractant receptors for the treatment of inflammatory diseases, autoimmune disorders, and cancer.
Its lead product, TAVNEOS (avacopan), is an oral complement C5a receptor inhibitor approved as an adjunctive therapy for adults with severe active ANCA-associated vasculitis. In October 2022, ChemoCentryx was acquired by Amgen for approximately $3.7 billion and now operates as a subsidiary, with its assets integrated into Amgen's portfolio.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
